

FORM PTO-1390 (Modified)
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES

216110US0PCT

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

09/926586

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/SE00/01024

22 May 2000

21 May 1999

TITLE OF INVENTION

NEW COMPOSITION

APPLICANT(S) FOR DO/EO/US

Anna BERGGREN, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Notice of Priority

Request for Consideration of Documents Cited in the International Search Report

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) 09/926586		INTERNATIONAL APPLICATION NO. PCT/SE00/01024		ATTORNEY'S DOCKET NUMBER 216110US0PCT	
--	--	--	--	---	--

24. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : <input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY <div style="border: 1px solid black; height: 100px; width: 100%;"></div>	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	20 - 20 =	0	x \$18.00	\$0.00	
Independent claims	2 - 3 =	0	x \$84.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,040.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$0.00	
SUBTOTAL =				\$1,040.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$1,040.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable) <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$1,040.00	
				Amount to be: refunded	\$
				charged	\$

a. ☒ A check in the amount of **\$1,040.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **15-0030** A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Telephone: (703)413-3000
 Fax: (703)413-2220
Surinder Sachar
Registration No. 34,423


22850

Surinder Sachar

SIGNATURE

Norman F. Oblon

NAME

24,618

REGISTRATION NUMBER

Nov. 21 2001

DATE

09/926586

216110US-0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF: :
ANNA BERGGREN ET AL : ATTN: APPLICATION DIVISION
SERIAL NO: NEW U.S. PCT APPLN :
(BASED ON PCT/SE00/01024)
FILED: HEREWITH :
FOR: NEW COMPOSITION

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows.

IN THE CLAIMS

Please cancel Claims 1-13.

Please add the following new claims.

14. (New) A sports drink, characterized in containing viable lactobacilli having a positive effect on human intestinal mucosa.

15. (New) A sports drink comprising micronutrients in combination with conventional additives for sports drinks, characterized in containing in addition viable lactobacilli having a positive effect on human intestinal mucosa.

16. (Amended) A sports drink according to claim 15, characterised in containing one or several strains of *Lactobacillus acidophilus*, *Lactobacillus casei*, *Lactobacillus fermentum*, *Lactobacillus paracasei*, *Lactobacillus plantarum*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus* in a therapeutically effective amount.

17. (Amended) A sports drink according to claim 15, wherein the micronutrients are selected from the group consisting of ascorbic acid, vitamin E, carotenoids, pyridoxine, thiamine, riboflavin, niacin, cobalamin, folacin, Q10, flavonoids, copper, magnesium, manganese, selenium, zinc and chromium.

18. (Amended) A sports drink according to claim 15, characterised in containing per 1000 g

ascorbic acid	500-1200 mg
vitamin E	250-375 mg
β -carotene	15-25 mg
pyridoxine	15-25 mg
sodium	20-60 mg
potassium	60-100 mg
copper	0.5-1.5 mg
magnesium	120-175 mg
manganese	1-3 mg
selenium	0.05-0.15 mg
zinc	5-15 mg

19. (Amended) A sports drink according to claim 15, which comprises proteins, optionally in combination with amino acids.

20. (New) A sports drink according to claim 19, wherein the protein is a whey protein or whey protein hydrosylate.

21. (Amended) A sports drink according to claim 15, which comprises carbohydrates having a low glycemic index, optionally in combination with carbohydrates of a high glycemic index.

22. (Amended) A sports drink according to claim 15, characterised in containing per 1000 g

whey proteins	15-60 g
carbohydrates	40-150 g
micronutrients	1-2 g
probiotic strain of	$5 \cdot 10^7 - 5 \cdot 10^8$ cfu/ml

Lactobacillus

23. (Amended) A sports drink according to claim 15, characterised in containing per 1000 g:

whey protein isolate	15-60 g
mono- and disaccharides	40-150 g
micronutrients	1-2 g
L. plantarum DSM 9843	$5 \cdot 10^7 - 5 \cdot 10^8$ cfu/ml

24. (Amended) Tablet for the preparation of a sports drink according to claim 15 in vivo or in vitro, characterised in that it comprises micronutrients in combination with freeze-dried, viable lactobacilli.

25. (Amended) Use of lactobacilli for the preparation of a sports drink according to claim 15 to prevent and treat stress symptoms, gastrointestinal disturbances, and lesions of the mucose membrane of the intestines.

26. (New) A sports drink according to claim 14, characterised in containing one or several strains of *Lactobacillus acidophilus*, *Lactobacillus casei*, *Lactobacillus fermentum*, *Lactobacillus paracasei*, *Lactobacillus plantarum*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus* in a therapeutically effective amount.

27. (New) A sports drink according to claim 14, which comprises proteins, optionally in combination with amino acids.

28. (New) A sports drink according to claim 27, wherein the protein is a whey protein or whey protein hydrolysate.

29. (New) A sports drink according to claim 27, which comprises carbohydrates having a low glycemic index, optionally in combination with carbohydrates of a high glycemic index.

30. (New) A sports drink according to claim 27, characterised in containing per 1000 g

whey proteins	15-60 g
carbohydrates	40-150 g
micronutrients	1-2 g
probiotic strain of	$5 \cdot 10^7 - 5 \cdot 10^8$ cfu/ml

Lactobacillus

31. (New) A sports drink according to claim 27, characterised in containing per 1000 g:

whey protein isolate	15-60 g
mono- and disaccharides	40-150 g
micronutrients	1-2 g
<i>L. plantarum</i> DSM 9843	$5 \cdot 10^7$ - $5 \cdot 10^8$ cfu/ml

32. (New) Tablet for the preparation of a sports drink according to claim 27 in vivo or in vitro, characterised in that it comprises micronutrients in combination with freeze-dried, viable lactobacilli.

33. (New) Use of lactobacilli for the preparation of a sports drink according to claim 14, to prevent and treat stress symptoms, gastrointestinal disturbances, and lesions of the mucose membrane of the intestines.

09/926586

REMARKS

Claims 14-33 are active in the present application. Claims 1-13 have been canceled.
Claims 14-33 are new claims. Support for the new claims is found in the original claims. No
new matter is added. An action on the merits and allowance of the claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Daniel J. Pereira, Ph.D.
Registration No. 45,518



22850

(703) 413-3000
Fax #: (703) 413-2220
NFO/DJP/law

I:\atty\SUKOS\216110US-PR.wpd

216110US-0PCT

Marked-Up Copy

Serial No: _____

Amendment Filed on: _____

11-21-01

IN THE CLAIMS

Claims 14-33 (New)..

NEW COMPOSITION

The present invention refers to a sports drink which should be taken in connection with training and competition, especially in so-called endurance sports, such as skiing, marathon running and bicycling.

BACKGROUND OF THE INVENTION

It is generally known that physical exercise requires an increased and nutritionally adequate liquid intake. Dehydration rapidly decreases the capacity of an individual, but in hard training and competition the administration of salts and carbohydrates is also required in order to maintain the fluid balance, a proper salt balance and the energy level.

There is on the market today a large number of fluid and/or energy providing beverages. So called sports drinks are normally intended to be taken directly during the physical exercise to meet with the loss of fluids and salts of the body. A sports drink can be hypotonic, that is have a lower content of salts and sugars than the human body fluid, which means that it is quickly taken up by the body. Such a beverage is well fitted for short training sessions. An isotonic sports drink, that is having about the same concentration of salts and sugars as the human body, may well be used during harder and longer training sessions. A conventional sports drink contains in addition to water, carbohydrates, such as different sugars, in an amount of 4-8 %, salts and minerals.

There are also different types of nutritional additives based on vitamins, minerals and other antioxidants, or in other ways stimulating substances such as caffeine or ginseng, which can either be provided in a sports drink or in the shape of tablets or powder or any other conventional form such as an energy cake.

In connection with physical exercise it is now generally believed that there is also an increased demand of proteins and many nutritional additive products therefore also contains one or more amino acids or proteins. This is especially true for products, which are used by body-builders and other strength sports performers.

When practising an endurance sport or exercising physically during a long period of time the body will be in a state of

stress. This implies an increased flow of blood to the muscles, increased production of free radicals, and increased level of the so called stress hormones adrenaline, noradrenaline and cortisol. This state of stress also leads to gastrointestinal problems for many people practising said sports, such as marathon runners and hard training athletes. The gastrointestinal problems can be manifested in many different ways, such as constipation, diarrhea, stomach ache, cramp or nausea (Nancy Rehrer et al., Gastrointestinal complaints in relation to dietary intake in triathletes, International Journal of Sport Nutrition, 1992, 2, 48-59). Competitive long-distance running is also said to induce gastrointestinal blood loss which may contribute to iron deficiency, runner's anaemia (James G. Stewart et al., Gastrointestinal Blood Loss and Anaemia in Runners, Annals of Internal Medicine, 1984, Vol. 100, No. 6, 843-845). Said intestinal bleedings might be due to a weakened intestinal mucosa.

PRIOR ART

GB 2 335 134 A, Stalplex Ltd, discloses a carbonated sport beverage comprising fruit juice, carbohydrates and a soluble whey protein hydrolysate. The beverage is to be used by people engaged in physical activities. Nothing is, however, stated about the optional effects of the beverage.

WO 89/08405, Nils Molin et al., describes a nutrient composition for administration to patients in feeding by tube or for use as a health drink. The nutrient composition comprises fermented oat-flour in combination with lactobacilli, optionally also soya flour or skim milk powder and supplementary mineral substances and vitamins. A nutrient composition should cover the total nutrient requirements and should contain carbohydrates, proteins and fat. The amount of antioxidants will on the other hand be fairly low.

There is therefore still a need for an improved sports drink which can allieviate the symptoms of prolonged physical activity.

DESCRIPTION OF THE INVENTION

The purpose of the invention is to provide a sports drink

which in addition to a nutrient and fluid supplementation before or after physical activity in order to build up and recover, respectively, the energy and fluid levels of the body, also relieves the symptoms of stress. It has now surprisingly been shown that viable lactobacilli can be mixed with micro-nutrients, carbohydrates, salts and proteins, without negative effects on e.g. antioxidants, to a beverage having a good taste and a good shelf-life.

The invention refers to a sports drink which is characterised in containing viable lactobacilli having a positive effect on human intestinal mucosa.

The invention especially refers to a sports drink which comprises micronutrients in combination with conventional additives for a sports drinks, which is characterised in that it also contains viable lactobacilli having a positive effect on human intestinal mucosa.

Lactobacilli which are suitable to use in accordance with the invention comprise those different strains of different species which have a positive effect on human intestinal mucosa. Such an effect involves an ability to colonise in the intestines and thereby protect the intestinal mucosa, for instance by initiating the production of mucin or short chain fatty acids. Examples of strains having this ability can be found among the following species *Lactobacillus acidophilus*, *Lactobacillus casei*, *Lactobacillus fermentum*, *Lactobacillus paracasei*, *Lactobacillus plantarum*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus*.

A suitable species of *Lactobacillus*, which can be used according to the invention, is a *Lactobacillus plantarum* being able to adhere to the intestinal epithel and colonise in the intestines. Particularly suitable strains of this species comprise a mannose specific adhesin, such as described in WO 96/29083, and are part of a cluster of *L. plantarum* having more than 70 % similarity to *L. plantarum* 299, deposited on July 2, 1991 at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany under the accession number DSM 6595, with respect to REA, that is restriction enzyme analysis of the total chromosomal DNA. A preferred strain is *L. plantarum* 299v, deposited on March 16, 1995 under the accession number DSM 9843.

Other strains of interest which can be used in a sports drink according to the invention are the probiotic strains *Lactobacillus rhamnosus* 271 (DSM 6594), *Lactobacillus rhamnosus* GG (ATCC 53103), *Lactobacillus casei rhamnosus* LB 21, *Lactobacillus casei* Shirota, *Lactobacillus johnsonii* Lj1, and *Lactococcus lactis* L1A.

Micronutrients in this context refers to vitamins, minerals and other additives having an antioxidising or stimulating effect. As examples can be mentioned:

Ascorbic acid or vitamin C, which acts as an antioxidant but also takes part in hydroxylation reactions. Lack of ascorbic acid can result in such symptoms as tiredness, weakness and also loosening of the teeth. According to the Swedish nutritional recommendations the intake should be 35-60 mg per day;

Carotenoids acts as antioxidants. The carotenoid group includes both carotenes and xanthophylls. The difference between them is the occurrence of oxygen in the xanthophyll molecule. Examples of carotenoids are α -carotene, β -carotene, γ -carotene, lycopene, lutein, chryptoxanthin, astaxanthin, canthaxanthin, and zeaxanthin. About 50 of approximately 500 naturally occurring carotenoids are precursors of retinol. E.g. β -carotene is a provitamin to vitamin A. The vitamin is needed for the sight, growth, reproduction and the normal differentiating and stability of the epithel tissues. A-vitamin is also considered to be of importance for the immune defence. The recommended daily intake of retinol equivalents for men is 1000 μ g and for women 800 μ g per day. Astaxanthin is a powerful antioxidant, which has proven to give an increased antibody production;

Vitamin E, natural or synthetic, is considered to function as an antioxidant and by that contribute to the stability of the cell membranes by protecting the polyunsaturated fatty acids in the lipids of the membranes. The recommended daily intake is 10 mg α -tocopherol equivalents for men and 8 mg for women;

Vitamin B6 is the common name for pyridoxine, pyridoxal and pyridoxamine. Lack of vitamin B6 is uncommon and in that case occurs together with lack of other B-vitamins. Symptoms are for instance cramps and anemia. The recommended intake is 1.5-2 mg per day and the need is proportional to the amount of protein, which is metabolized in the body;

Thiamin, vitamin B1, acts as a coenzyme in several enzymes of importance for the energy metabolism in e. g. the citric acid cycle. A lack thereof can cause beriberi, which involves disorders of the nerve system, heart and digestion organs. An intake of 0.5 mg per 1000 kcal is believed to give tissue saturation, the recommendations are 1 mg and above;

Riboflavin, vitamin B2, takes part in the conversion of tryptophane into niacin. A lack thereof is generally connected to a deficiency of other B-vitamins and symptoms of this deficiency can be hypersensitivity to light and reddening mouth mucosa. Recommended intake is 1.6 mg per day for men and 1.3 mg for women;

Niacin, nicotinic acid, is a part of coenzymes and constitutes a part of NAD and NADP, which are necessary in the conversion of glucose, amino acids and fat. Lack thereof can result in pellagra. Characteristics are changes in the skin, gastro-intestinal system. Recommended intake of niacin should be proportional to the consumption of energy and is about 13-18 mg per day;

Cobalamin, vitamin B12, acts as a coenzyme in transferring one-carbon groups and takes part, together with folic acid, in the formation of active methyl groups. Vitamin B12 deficiency can result in pernicious anaemia and also cause nerve damages. According to Swedish nutritional recommendations 3 μ g per day is regarded to cover the requirement;

Folacin, folic acid, acts as a coenzyme and transfers one-carbon fragments in amino acid synthesis and nucleic acid synthesis. Folacin deficiency results in impaired cell division, disordered protein conversion and megaloblastic anaemia. Recommended intake of folacin is 200 μ g per day;

CoQ10 or coenzyme Q10 is an antioxidant protecting against free radicals, in particular oxidation of lipids is prevented. In general about 100 mg per day is given;

Flavonoides, which are present in vegetable food, are powerful polyphenolic antioxidants preventing oxidation of lipoproteins and reducing the risk of coronary heart diseases;

Copper is part of enzymes, which are necessary for the energy metabolism of the cells, synthesis of connective tissue, synthesis of neuropeptides and in the body defence against free

radicals. Deficiency symptoms in adults are dysarrhythmia and other changes of the heart function. Recommended intake is 1.2 mg for adults;

Magnesium is the prosthetic group of many enzymes and also functions as an activator. ATP:ase is for instance magnesium dependent and is part of inter alia the contraction of the muscle cells, the Na/K-pump. Magnesium is also needed for nucleic acid and protein synthesis. In addition, the function of certain nerve cells depends on magnesium. Recommended intake of magnesium is 280 mg per day for women and 350 mg for men;

Manganese inter alia takes part of the synthesis of proteins, mucopolysaccharides and cholesterol. Possible symptoms of manganese deficiency in man are changes of the skin and hypocholesterolemia. Recommended intake is 25 mg per day;

Selenium mainly is part of the enzyme glutathioneperoxidase and protects the cells from oxidative lesions. The recommended intake of selenium is 40 μg for women and 50 μg for men. The intake should not exceed 5 μg per kg body weight and day. Selenium deficiency can cause a heartmuscle disease;

Zinc is a part of many enzymes. Zinc deficiency can be manifested as growth retardation and changes of the skin. Recommended intake of zinc according to the Nordic nutritional recommendations is 7 mg for women and 9 mg for men. Too high an intake negatively effects the metabolism of other trace elements. The zinc intake should not exceed 45 mg for adults and 25 mg for children;

Chromium is the biological active component of the glucose tolerance factor, which potentiates the insulin activity. A supplement of chromium could improve the efficiency of insulin.

The invention especially refers to a sports drink containing micronutrients selected from the group consisting of ascorbic acid, vitamin E, carotenoids, pyridoxine, thiamine, riboflavine, niacin, cobalamine, folacin, Q10, flavonoides, copper, magnesium, manganese, selenium, zinc, and chromium. A synergistic effect can be expected for a mixture of the stated compounds. It is for instance well known that vitamin C, vitamin E and selenium have a synergistic effect.

Salts of sodium and potassium are necessary to administer after exercise in order to recover the salt balance; this is

true especially in a warm climate with attendant perspiration. Acute salt deficiency causes nausea and impaired nerve impulses, which inter alia is manifested in a swaying and stumbling gait. Moderately high levels of sodium, such as up to 50-60 mmol/l, and also some potassium should therefore be part of the composition according to the invention in order to compensate for losses through perspiration.

A preferred combination of micronutrients and salts in a sports drink according to the invention is, per 1000 g sports drink:

ascorbic acid	500-1200 mg
vitamin E	250-375 mg
β -carotene	15-25 mg
pyridoxine	15-25 mg
sodium	20-60 mg
potassium	60-100 mg
copper	0.5-1.5 mg
magnesium	120-175 mg
manganese	1-3 mg
selenium	0.05-0.15 mg
zinc	5-15 mg

According to a preferred aspect the invention refers to a sports drink, which in addition to micronutrients and live lactobacilli also comprises proteins.

Proteins, which are suitable to use in a sports drink according to the invention, should be water soluble, acid stable and heat stable. As examples can be mentioned different milk proteins, especially whey proteins or whey protein hydrolysates. Whey protein isolates are one of the protein sources supplying most essential amino acids and branched amino acids per g of nitrogen. A preferred whey protein is highly soluble in water and forms low viscous, homogenous and comparatively clear solutions after mixing with water. Another possible source of proteins is bovine colostrum. Different amino acids, especially branched amino acids which are taken up by the muscles, can also be added to give a corresponding supplement of energy. Essential, branched amino acids, which can be added with the whey protein, are leucine, isoleucine and valine.

The sports drink of the invention also contains carbohydrates and salts in an aqueous solution, preferably flavoured with a fruit juice concentrate and aromas.

Preferred carbohydrates are the so-called slow carbohydrates, having a low glycemic index. GI, glycemic index, is a measure of how quickly the carbohydrates of a food enter the blood. Fructose is the monosaccharide having the lowest glycemic index and is particularly preferred. If you wish to prepare a beverage which is hypotonic it could, however, be adequate to use a so called polysugar, maltodextrin, which has a high carbohydrate concentration but a low osmotic pressure, in an amount of 2-20 dextrose equivalents. For different reasons it might, however, be preferred to use the slow carbohydrate in admixture with a carbohydrate having a high glycemic index, for instance other mono- or disaccharides, such as glucose and saccharose.

If the monosaccharide content is lower than 50 g per 1000 g, an isotonic beverage is obtained; at higher contents a hypotonic beverage. If this beverage also contains salt the amount will be different.

Aromas can for instance be produced from different concentrated fruit juices and is preferably used when the sport drinks contain proteins, especially whey proteins, which might otherwise give the beverage a special, bitter taste.

A sports drink according to the invention can for instance per 1000 g contain:

whey protein	15-60 g
carbohydrates	40-150 g
micronutrients	1-2 g
probiotic strain of	$5 \cdot 10^7$ - $5 \cdot 10^8$ cfu/ml
<i>Lactobacillus</i>	

According to a preferred aspect of the invention the sports drink contains per 1000 g:

whey protein isolate	15-60 g
mono- and disaccharides	40-150 g
micronutrients	1-2 g
<i>L. plantarum</i> DSM 9843	$5 \cdot 10^7$ - $5 \cdot 10^8$ cfu/ml

According to another aspect the invention refers to a nutritional additive comprising micronutrients in combination with freeze-dried, viable lactobacilli, especially in the shape of a tablet or a powder. This nutritional additive can also be an energy cake or some other conventional nutritional product wherein the lactobacilli can be preserved alive.

The invention especially refers to a tablet for preparing of a sports drink as above, which tablet comprises micronutrients in combination with freeze-dried, viable lactobacilli. Such a tablet can be prepared by mixing a freeze-dried culture, in an amount of 10-20 % by weight of the total composition, of selected lactobacilli with micronutrients, 1-3 %, and an adequate tablet making material which allows for the use of a comparatively low punching pressure at the tableting, for instance according to the process which is described in WO 97/07822. By using a reduced punching pressure it will be possible to maintain 90-95 % of the viability of the bacteria. Possible tablet making materials are poly- and oligosaccharides, especially based on fructose, calcium diphosphate, micro-crystalline cellulose and maltodextrine as a filler, xanthan as a slime forming agent and magnesium stearate as a lubricant. The tablet can also be an effervescent.

By mixing a tablet prepared in this way with water or with water and carbohydrates, with or without proteins and salts, or with a conventional sports drink, a sports drink according to the invention for direct consumption is obtained. It is of course also possible to make the mixture in vivo, that is to eat the tablet in connection with the intake of the fluid.

A hypertonic sports drink according to the invention containing proteins, carbohydrates and lactobacilli can preferably be taken before or after competition or training in an amount of $\frac{1}{2}$ to 1 litre per day. This corresponds to a total daily consumption of $3 \cdot 10^{10}$ - $5 \cdot 10^{10}$ cfu/ml. The beverage is, owing to its content of proteins and lactobacilli, less apted for being taken during the physical exercise. There is, however, nothing that prevents the use of a beverage consisting of hypertonic amounts of carbohydrates and salts and micronutrients in combination with lactobacilli and optimal flavouring additives also during the physical exercise as such.

The invention in addition refers to the use of lactobacilli for the preparation of a sports drink to be used to prevent and treat stress symptoms, disturbances of the gastrointestinal tract, and lesions of the mucose membrane of the intestines. It has been shown that a regular intake of a sports drink according to the invention has a positive effect on the stress related gastrointestinal problems. By taking this beverage the negative effect of stress is reduced, the risks of disorders in stomach and intestines are decreased and, especially, the risk of disorders of the intestinal mucosa is reduced.

It is probable that the most favorable effect on the intestinal mucosa is obtained with a sports drink containing a combination of whey protein, micronutrients and lactobacilli.

EXAMPLES

Example 1. Hypertonic sports drink

For the preparation of a hypertonic sports drinks the following constituents are used

whey proteins	22.5 g
fructose	20 g
glucose	60 g
saccharose	40 g
oatbase	50 g
micronutrients	1.5 g
fruit juice concentrate	15 g
aromas	1.5 g
water	q. s. ad 1000 g
citric acid for adjusting pH to 3.4	

All the constituents are weighed. The whey protein, Lacprodan® DI-9213 (MD-Foods, Viby, Denmark), is mixed with water and then homogenised on ultraturrax, position 2 (13,000 rpm), for about 1 minute. Then fructose, glucose and saccharose, and aromas are added, mixed and heated during stirring to 90°C for 5 minutes in a water-bath. The fruit juice concentrate could be from lemon-lime, black current or tropical, all from Skånemejerier Ekonomisk förening, Malmö. The aroma has a lemon-lime taste and has been obtained from Quest International, Lund. The batch is then cooled to room temperature and the oatbase which contains *Lactobacillus plantarum* 299v in an amount of

$1-2 \cdot 10^9$ cfu per ml, and micronutrients are added. After mixing a well tasting beverage is obtained which is aseptically packed and then cool stored.

The micronutrients and the proportion between them are, calculated on the metal when applicable, as follows

ascorbic acid	800 mg
vitamin E	320 mg (400 IE)
β -carotene	20 mg
pyridoxine	20 mg
copper (CuSO_4)	1 mg
magnesium (MgO)	150 mg
manganese (Mn_2SO_4)	2 mg
selenium (Na_2SeO_3)	100 μg
zinc (ZnSO_4)	10 mg

and constitutes a powder mixture.

The oatbase used above is a storage solution of lactobacilli and is prepared from oat meal, malt flour and water which are mixed and heated at different temperature ranges to give a proper substrate for the selected strain of *Lactobacillus*. In this case *Lactobacillus plantarum* DSM 9843 is used, which is added to the cooled oats mixture and which after fermentation gives a content of about $2 \cdot 10^9$ cfu/ml oatbase.

The sports drink thus prepared contains per 100 g

protein	2.1 g
fat	0.1 g
carbohydrates	13 g
sodium	2.3 mg
potassium	6.4 mg
lactobacilli	$5 \cdot 10^7$ cfu/ml

The shelf-life of the prepared sports drink has turned out to be at least 4 weeks when stored in a refrigerator, +4 to +8°C.

Example 2. Hypertonic sports drink

For the preparation of another hypertonic sports drinks the following constituents are used

Lacprodan® DI-9213	45 g
fructose	120 g

oatbase	50 g
micronutrients	1.5 g
fruit juice concentrate	20 g
aromas	1.5 g
water	q. s. ad 1000 g

The same procedure as described in Example 1 was followed, the same micronutrients and lactobacilli were added and the sports drink thus prepared contained per 100 g

protein	4 g
fat	0.1 g
carbohydrates	13 g
sodium	4.5 mg
potassium	8.6 mg
lactobacilli	$5 \cdot 10^7$ cfu/ml

Example 3. Tablet

The following ingredients are mixed in the stated weight proportion

<i>L. plantarum</i> DSM 9843, freeze-dried	20 %
inulin	78 %
micronutrients	2 %

and compressed into tablets. The micronutrients have the composition stated in Example 1 above. 1 tablet could preferably be taken together with about ½ litre of fluid.

Example 4. Tablet

In the same way as in Example 3 the following ingredients are mixed, giving a tablet having improved solubility properties.

<i>L. plantarum</i> DSM 9843, freeze-dried	10 %
inulin	85 %
micronutrients	2 %
magnesium stearate	1 %
xanthan	2 %

BIOLOGICAL TESTS

Effects of *L. plantarum* DSM 9843 in a rat intestinal bleeding model

36 male Sprague-Dawley rats were used for the experiment. They were housed in separate metabolic cages to collect stool individually for evaluation. The animals were kept at room temperature, 22°C, with a controlled 12 h light/dark cycle and had free access to standard rat chow and drinking water. There were three different experimental groups with 12 rats in each. Group 1 was the negative control which received no treatment. Group 2 was the positive control which was given DSS, dextrane sulphate, in order to induce intestinal bleeding. The rats in Group 3 were treated with DSS + *L. plantarum* DSM 9843. All rats underwent sham operation for insertion of a pump for a later experiment under anaesthesia. On day 1 the rats were operated and on the following 6 days DSS was administered. Group 1 had free access to tap water and Groups 2 and 3 received ad libitum 5 % (w/v) DSS (ICN Biomedicals Inc. Aurora, Ohio, USA) dissolved in the drinking water. The Group 3 rats were fed enterally with an oatmeal drink containing 1×10^{10} cfu/ml of *L. plantarum* DSM 9843 twice daily in a volume of 2 ml through an oro-gastric tube.

The following results were obtained

Table 1. Mean of Disease Activity Index

day	Group 1	Group 2	Group 3
1	0.3	0.4	0.2
2	0.1	0.5	0.6
3	0.0	0.5	0.5
4	0.0	0.8	0.9
5	0.1	1.5	1.0*
6	0.2	2.3	1.8*
7	0.0	2.8	2.3*

* denotes $P < 0.05$ compared to Group 2, that is the DSS group

The Disease Activity Index, which is a combination of scores for weight loss, stool consistency and bleeding, divided by 3, was

scored as below

Table 2. Scoring of Disease Activity Index

Score	Weight loss, %	Stool consistency	Bleeding
0	none	normal = well-formed pellets	negative
1	1-5		
2	5-10	loose stool = pasty, not sticking to the anus	hemoccult +
3	10-20		
4	>20	diarrhea = liquid stool sticking to the anus	gross bleeding

The results of this test show that administration of *Lactobacillus plantarum* to the intestines has a positive effect on the intestinal mucosa.

Pilot study with the Sports drink of Example 1

7 hard training persons, No. 1-7, were given the sports drink according to Example 1 and were told to take $\frac{1}{2}$ to 1 liter per day before or after the physical exercise for a period of 4 weeks. They were also asked to give their views on optional differences as to gastrointestinal behaviour, recovery, sense of well-being, ache after training and optional other aspects.

Person No.1 is a long-distance runner training more than 7 times a week. He experienced no gastrointestinal problems during the test. From day 5 he finds that his capacity and total well-being had increased. After 28 d the ache after training has decreased.

Person No. 2 is a handball player, and mentions less ache after training and increased well-being.

Person No. 3 is an athlete. In addition to an increased well-being she believes that the recovery is quicker and sometimes the performance better.

Person No. 4 is a marathon runner. He liked the drink and found it of value during hard training, but finds the test

period of 4 weeks to be too short. He had rarely any gastrointestinal problems - only during extremely intensive training sessions.

Person No. 5 is a marathon runner who mentions less ache after training, increased well-being and good recovery. Above all she is happy with an improved gastrointestinal behaviour, previous diarrhea after hard training has disappeared and she has no longer any gastrointestinal problems.

Person No. 6 is an athlete, running 400 and 800 m. She found the drink to increase her well-being, reduce the ache after training, reduce the disease frequency, increase the recovery rate.

Person No. 7 is an athlete, running middle distances. She experienced an improved gastrointestinal behaviour, an increased recovery rate, a reduced infection frequency and in general an improved total well-being.

The conclusions from this pilot study are that those individuals who had gastrointestinal problems in connection with hard training experienced a clear improvement; the reduction of the ache after training was also a common feature.

Studies in progress

In order to closer investigate the effects of the sports drink of the invention different tests are to be performed. In one study different parameters, such as antioxidative capacity in blood, gastrointestinal function and optional effects on the microflora, are to be studied on healthy persons having a high tempo in their working life. Another study is to be made with hard training athletes, in which maximum oxygen uptake, lactate threshold values, anaerobic capacity and power of endurance are to be tested.

In connection with a marathon competition the runners will be asked to participate in a study to evaluate the effects of the sports drink of the invention in reducing the occurrence of faecal blood.

Applicant's or agent's file reference	HeL/UB 43541	International application PCT/SE00/01024
--	--------------	---

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on page <u>3</u> , line <u>38 - 39</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution DSM-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH	
Address of depositary institution (including postal code and country) Mascheroder Weg 1B D-38124 Braunschweig Germany	
Date of deposit 16 March 1995	Accession Number DSM 9843
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
For receiving Office use only	For International Bureau use only
<input checked="" type="checkbox"/> This sheet was received with the international application 22-05-2000	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer <i>Inger Willén</i> Inger Willén	Authorized officer

20-08-2001

16

CLAIMS

1. A sports drink comprising micronutrients in combination with conventional additives for sport drinks, characterized in containing 1-2 g of micronutrients selected from the group consisting of ascorbic acid, vitamin E, β -carotene, pyridoxine, thiamine, riboflavin, niacin, cobalamin, folacin, Q10, copper, magnesium, manganese, selenium, zinc and chromium, per 1000 g in combination with viable lactobacilli having a positive effect on human intestinal mucosa.

2. A sports drink according to claim 1, characterised in containing one or several strains of *Lactobacillus acidophilus*, *Lactobacillus casei*, *Lactobacillus fermentum*, *Lactobacillus paracasei*, *Lactobacillus plantarum*, *Lactobacillus reuteri*, *Lactobacillus rhamnosus* having the ability to colonise in the intestines, in a therapeutically effective amount.

3. A sports drink according to claim 1 or 2, characterized in containing the micronutrients vitamin C, vitamin E, and selenium.

4. A sports drink according to any of claims 1-3, characterized in containing the micronutrients ascorbic acid, vitamin E, β -carotene, pyridoxine, copper, magnesium, manganese, selenium, and zinc.

5. A sports drink according to any of claims 1-4, characterised in containing per 1000 g

ascorbic acid	500-1200 mg
vitamin E	250-375 mg
β -carotene	15-25 mg
pyridoxine	15-25 mg
sodium	20-60 mg
potassium	60-100 mg
copper	0.5-1.5 mg
magnesium	120-175 mg
manganese	1-3 mg
selenium	0.05-0.15 mg
zinc	5-15 mg

6. A sports drink according to any of claims 1-5, which comprises proteins, optionally in combination with amino acids.

7. A sports drink according to claim 6, wherein the protein is a whey protein or whey protein hydrolysate.

8. A sports drink according to any of claims 1-7, which comprises carbohydrates having a low glycemic index, optionally in combination with carbohydrates of a high glycemic index.

9. A sports drink according to any of claims 1-8, characterised in containing per 1000 g

whey proteins	15-60 g
carbohydrates	40-150 g
micronutrients	1-2 g
a probiotic strain of	
<i>Lactobacillus plantarum</i>	$5 \cdot 10^7$ - $5 \cdot 10^8$ cfu/ml

10. A sports drink according to any of claims 1-9, characterised in containing *Lactobacillus plantarum* 299v (DSM 9843).

11. A sports drink according to any of claims 1-10 for use as a medicament for increasing the antioxidative capacity.

12. Tablet for the preparation of a sports drink according to any of claims 1-10 in vivo or in vitro, characterised in that it comprises micronutrients in combination with freeze-dried, viable lactobacilli.

13. Use of lactobacilli for the preparation of a sports drink according to any of claims 1-10 to prevent and treat stress symptoms, gastrointestinal disturbances, and lesions of the mucous membrane of the intestines.

Declaration, Power Of Attorney and Petition

Page 1 of 3

WE (I) the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name,

We (I) believe that we are (I am) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

New composition

the specification of which

☐ is attached hereto.

☐ was filed on _____ as

Application Serial No. _____

and amended on _____.

☒ was filed as PCT international application

Number PCT/SE00/01024

on May 22, 2000,

and was amended under PCT Article 19

on _____ (if applicable).

We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We (I) acknowledge the duty to disclose information known to be material to the patentability of this application as defined in Section 1.56 of Title 37 Code of Federal Regulations.

We (I) hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s)

Application No.	Country	Day/Month/Year	Priority Claimed
<u>9901856-6</u>	<u>Sweden</u>	<u>21 May 1999</u>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No

We (I) hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

_____ (Application Number)	_____ (Filing Date)
_____ (Application Number)	_____ (Filing Date)

We (I) hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or under § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status (pending, patented, abandoned)
PCT/SE00/01024	22 May 2000	_____
_____	_____	_____
_____	_____	_____

And we (I) hereby appoint the following registered practitioner(s):



022850

as our (my) attorneys, with full powers of substitution and revocation, to prosecute this application and to transact all business in the Patent Office connected therewith; and we (I) hereby request that all correspondence regarding this application be sent to




022850

We (I) declare that all statements made herein of our (my) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

002- Anna Berggren
NAME OF FIRST SOLE INVENTOR

Residence: Tulpanvägen 9, S-240 32

Flyinge, Sweden 52X


Signature of Inventor

Citizen of: Sweden

Mailing Address: Same as above

29/10 2001
Date

200
Marie Louise Johansson
NAME OF SECOND JOINT INVENTOR

Marie Louise Johansson
Signature of Inventor

October 29, 2007
Date

30
Kåre Larsson
NAME OF THIRD JOINT INVENTOR

Kåre Larsson
Signature of Inventor

31/10, 2001
Date

40
Anne-Marie Lindberg
NAME OF FOURTH JOINT INVENTOR

Anne-Marie Lindberg
Signature of Inventor

29.10.2001
Date

50
Jörgen Wiklander
NAME OF FIFTH JOINT INVENTOR

Jörgen Wiklander
Signature of Inventor

22/10 2001
Date

Residence: Flygelvägen 14, S-224 72
Lund, Sweden SEX

Citizen of: Sweden

Post Office Address: Same as above

Residence: Norra Villavägen 7B, S-237 34
Bjärred, Sweden SEX

Citizen of: Sweden

Post Office Address: Same as above

Residence: Källarekroken 6, S-226 47
Lund, Sweden SEX

Citizen of: Sweden

Post Office Address: Same as above

Residence: Älta Strandväg 31, S-138 33
Älta, Sweden SEX

Citizen of: Sweden

Post Office Address: Same as above